Testing the Water: RainDance is Stalking Cancer Drop by Drop
Testing the Water: RainDance is Stalking Cancer Drop by Drop
RainDance Technologies is developing new "liquid biopsy" systems using tiny droplets separated by oil to analyze DNA. Researchers using the technology are evaluating its ability to identify whether the samples may contain cancer, viruses, pathogens and markers released by the immune system.
The new tools could allow doctors to test tumors and cancer cells with a simple needle prick. RainDance, which is based in Billerica, Mass, just received a new $16.5 million round of financing from a group of investors including GE's venture capital arm, GE Ventures.